Related Experiment Videos
Olfactory neuroblastoma: past, present, and future?
Valerie J Lund1, David Howard, William Wei
1Institute of Laryngology and Otology, University College London, 330 Gray's Inn Road, London WC1X 8DA, UK. v.lund@ucl.ac.uk
The Laryngoscope
|March 5, 2003
Summary
Craniofacial resection with radiotherapy offers the gold standard for treating olfactory neuroblastoma, demonstrating significant long-term survival rates. This approach should be the benchmark for evaluating alternative treatments like endoscopic resection.
Area of Science:
- Oncology
- Neurosurgery
- Head and Neck Surgery
Background:
- Olfactory neuroblastoma is a rare malignancy requiring effective treatment strategies.
- Long-term outcomes for patients treated with craniofacial resection are not well-established.
Purpose of the Study:
- To evaluate the long-term survival and outcomes of olfactory neuroblastoma patients treated with craniofacial resection.
- To identify prognostic factors influencing patient outcomes.
Main Methods:
- A single-center prospective cohort study analyzed 42 patients over 23 years.
- All patients underwent craniofacial resection, with or without radiotherapy.
- Multivariate analysis, including Cox regression, was performed to identify outcome predictors.
Main Results:
- Disease-free survival at 5 and 10 years was 77% and 53%, respectively.
- Overall survival at 5 and 10 years was 61% and 42%, respectively.
- Intracranial extension and orbital involvement were independent negative prognostic factors.
Conclusions:
- Craniofacial resection combined with radiotherapy represents the gold standard treatment for olfactory neuroblastoma.
- This established approach serves as a benchmark for comparing novel treatments like endoscopic resection.